Overview
Surgical aesthetics firm's Q4 revenue rose 34.7% yr/yr, beating analyst expectations
Adjusted EBITDA for Q4 was positive, beating analyst estimates
Company scaling U.S. launch of AYON Body Contouring System amid strong demand
Outlook
Apyx Medical expects FY2026 total revenue between $57.5 mln and $58.5 mln
Company anticipates FY2026 Surgical Aesthetics revenue between $53 mln and $54 mln
Apyx Medical projects FY2026 OEM revenue to be approximately $4.5 mln
Result Drivers
AYON LAUNCH - Scaling U.S. commercial launch of AYON Body Contouring System to meet strong market demand
SURGICAL AESTHETICS GROWTH - Surgical Aesthetics revenue increased 38.1% in Q4 2025, driven by U.S. sales of AYON
OEM REVENUE INCREASE - OEM revenue rose 15.6% in Q4 2025, but future focus remains on Surgical Aesthetics
Company press release: ID:nGNX5wHZMQ
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Beat | $19.16 mln | $18.40 mln (4 Analysts) |
Q4 EPS | -$0.03 | ||
Q4 Net Income | -$1.24 mln | ||
Q4 Adjusted EBITDA | Beat | $689,000 | $3,000 (3 Analysts) |
Q4 Gross Margin | 62.60% | ||
Q4 Income From Operations | $11,000 | ||
Q4 Pretax Profit | -$1.15 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Apyx Medical Inc is $5.50, about 60.3% above its March 9 closing price of $3.43
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments